Basque Basque
en Englishaf Afrikaanssq Albanianar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbg Bulgarianca Catalanzh-CN Chinese (Simplified)zh-TW Chinese (Traditional)hr Croatiancs Czechda Danishnl Dutchet Estoniantl Filipinofi Finnishfr Frenchgl Galicianka Georgiande Germanel Greekht Haitian Creoleiw Hebrewhi Hindihu Hungarianis Icelandicid Indonesianga Irishit Italianja Japaneseko Koreanlv Latvianlt Lithuanianmk Macedonianms Malaymt Malteseno Norwegianfa Persianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsw Swahilisv Swedishth Thaitr Turkishuk Ukrainianur Urduvi Vietnamesecy Welshyi Yiddish

Azken Albisteak

FDA Lifts-ek UniQure-ren Hemofilia B Gene Terapia Programa mantentzen du

 

Roctavian, Potentzial Hemofilia A Terapia Genetikoa, Lortu FDAren Laguntza Berria

 

Hemofilia B Terapia Genetikoa AMT-061 Nekez eragingo du gibeleko tumorea

 

SPK-8016 Terapia Genetikoak A Hemofilia Larriarekiko Goiz Agindua erakusten du

 

Gora joan
Irudia

Please enable the javascript to submit this form

buruz

Bayer, BioMarin, Freeline Therapeutics Limited, Pfizer Inc., Shire, Spark Therapeutics eta uniQure, Inc.-en hezkuntza bekek lagunduta.

SSL funtsezkoa